NBTXR3 treatment induces antitumoral immune response in human soft tissue sarcoma

Connective Tissue Oncology Society Annual Meeting (CTOS), Maui, Hawaii · 2017, Galon J. et al.

Nano Publications > Abstracts > Donnée clinique de NBTXR3 > STM > 2017 – Abstract – CTOS – NBTXR3 induces antitumoral immune response in human STS

Authors

Jerome Galon1, Marick Laé8, Zsuzsanna Papai2, Sebastien Carrere3, Juliette Thariat4, Philippe Rochaix5, Laszlo Csaba Mangel6, Zoltan Sapi7, Martine Delannes5, Anne Vincent-Salomon8, Isabelle Peyrottes9, Carmen Llacer3, Raphael Tetreau3, Marie-Christine Château3, Sylvie Bonvalot8
1 – INSERM, Paris, France
2 – Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary
3 – Institut du Cancer de Montpellier, Montpellier, France
4 – Centre François Baclesse, Caen, France
5 – IUCT Oncopole, Toulouse, France
6 – Pecs university, Pecs, Hungary
7 – Semmelweis University, Budapest, Hungary
8 – Surgery, Institut Curie, Paris, France
9 – Centre Antoine Lacassagne, Nice, France

Summary

The enclosed abstract was presented at the 2017 Connective Tissue Oncology Society Annual Meeting (CTOS), Maui, Hawaii. The abstract NBTXR3 Treatment Induces Antitumoral Immune Response in Human Soft Tissue Sarcoma describes how NBTXR3 activated by RT triggers an enhanced adaptive immune response and contributes to transform “cold” tumor into “hot” tumor.

Read Article

Contact

Pour plus d’informations, contactez notre équipe des affaires médicales à l’adresse medicalaffairs@nanobiotix.com